The 2026 Regulatory Landscape: FDA Monograph Reform
The US FDA has reached a milestone in 2026 with a major public meeting focused on increasing access to nonprescription drugs. This follows the 2025 implementation of the ACNU (Additional Condition for Nonprescription Use) rule.
Rx-to-OTC Switches: The FDA is currently evaluating "behind-the-counter" status for several chronic medications, including certain Statins and Migraine treatments, which would allow pharmacists to dispense them without a doctor's prescription.
Streamlined Labeling: New "Smart Labels" are now mandated for certain categories. These include QR codes that link to real-time AI-driven video instructions, significantly reducing "medication errors" caused by poor health literacy.
HHS OIG Bulletin (Jan 2026): A new bulletin clarifies how manufacturers can sell direct-to-consumer (DTC) at lower cash prices without violating federal anti-kickback statutes, provided the products are not billed to Medicare or Medicaid.